Johnson & Johnson to Acquire Ambrx Biopharma in $2 Billion Deal

The acquisition will bolster Johnson & Johnson's position in targeted oncology therapeutics, with the deal set to close in the first half of 2024.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here